目次

Table of Content

List of Figures & Tables

1. Introduction To Tetraspecific Antibodies
1.1 Clinical Relevance
1.2 Historical Evolution

2. Tetraspecific Antibodies Mechanism Of Action
2.1 Multispecific Antibody Formats
2.2 Immune Synapse Formation and Target Engagement

3. Tetraspecific Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Indication

4. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
4.1 Preclinical
4.2 Phase I
4.3 Phase I/II
4.4 Phase II

5. Current Clinical Development and Future Commercialization Outlook
5.1 Current Development Landscape
5.2 Future Commercialization Potential and Opportunities

6. Tetraspecific Antibodies Therapeutic Application By Indication
6.1 Cancer
6.1.1 Solid Tumors
6.1.2 Hematological Disorders 6.2 Autoimmune and Inflammatory Diseases

7. Tetraspecific Antibody Clinical Development Trend Analysis By Region
7.1 China
7.2 US
7.3 Europe

8. Tetraspecific Antibodies Proprietary Technologies By Company
8.1 Established Platforms
8.2 Emerging Platforms

9. Tetraspecific Antibodies Therapeutic Approaches
9.1 Monotherapy Use
9.2 Combination Therapy Strategies
9.3 Precision Targeting Applications

10. Competitive Landscape
10.1 Beijing StarMab Biomed Technology
10.2 Cellemedy
10.3 Innate Pharma
10.4 ModeX Therapeutics (OPKO Health)
10.5 Molecular Partners
10.6 QLSF Biotherapeutics
10.7 Sichuan Baili Pharmaceutical
10.8 SystImmune

List of Figures & Tables
Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells and NK Cells In Close Proximity
Figure 3-1: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2025
Figure 3-2: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2025
Figure 3-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2025
Figure 3-4: Global - Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2025
Figure 5-1: Global Tetraspecific Antibody Market - Future Opportunities
Figure 6-1: GNC-039-101 Phase I Study (NCT04794972) - Initiation and Completion Year
Figure 6-2: GNC-035-103 Phase I Study (NCT05160545) - Initiation and Completion Year
Figure 6-3: MDX-2001-101 Phase I/II Study (NCT06239194) - Initiation and Completion Year
Figure 6-4: GNC-038-105 Phase I/II (NCT05627856) Study - Initiation and Completion Year
Figure 6-5: GNC-038 Phase I/II Study (NCT05485753) - Initiation and Completion Years
Figure 6-6: GNC-035-104 Phase I/II (NCT06066203) Study - Initiation and Completion Years
Figure 6-7: GNC-035-105 Phase I/II (NCT05944978) Study - Initiation and Completion Years
Figure 6-8: GNC-035-101 Phase I/II (NCT05104775) Study - Initiation and Completion Years
Figure 6-9: MP0533-CP101 Phase I/II (NCT05673057) Study - Initiation and Completion Year
Figure 6-10: IPH6501-101 Phase I/II (NCT06088654) Study - Initiation and Completion Year
Figure 6-11: GNC-038-106 Phase I (NCT06857214) Study - Initiation and Completion Year
Figure 6-12: GNC-039 Phase I Study (NCT04794972) - Initiation and Completion Year
Figure 7-1: Sichuan Biokin Pharmaceutical - Clinical Pipeline
Figure 7-2: ModeX Therapeutics - Pipeline
Figure 7-3: Mechanism of Action - IPH6501 vs. MP0533
Figure 8-1: DARPin Platform - Molecular Partners
Figure 8-2: ANKETandreg; Platform - Innate Pharma
Figure 8-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 8-4: STEALTH - ModeX Therapeutics
Figure 8-5: MSTAR - ModeX Therapeutics
Figure 8-6: MSTAR - Salient Features
Figure 8-7: TECAD - QLSF Biotherapeutics
Figure 8-8: Multispecific VHH Antibody Drug Platform - Beijing StarMab Biomed Technology
Figure 8-9: MATCH - Numab
Figure 8-10: BiXAb - Features
Figure 8-11: Zybody - Zyngenia
Figure 8-12: T-sphaera - Cutting-Edge Plug-and-Play Platform for Drug Development
Figure 9-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 9-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 9-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 9-4: IPH6501 - Tetraspecific NK Cell Engager
Figure 9-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 9-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 9-7: Novel Tetraspecific Format Developed By The Roche Pharma Research and Early Development
Table 6-1: Hematological Cancers - Ongoing Clinical Trial For GNC-038
Table 7-1: China - Ongoing Tetraspecific Antibody Clinical Trials
Table 9-1: Monotherapy Clinical Trials For Tetraspecific Antibodies